Protagenic Therapeutics, Inc. operates as a biopharmaceutical firm dedicated to the research and development of novel treatments designed to address neuropsychiatric and mood conditions exacerbated by stress. Foremost among its investigational products is PT00114, a laboratory-synthesized version of the teneurin carboxy-terminal associated peptide. This compound functions by emulating an innate brain signaling peptide, known for its ability to temper exaggerated stress reactions. The company's headquarters are located in New York, New York.
Show more...
FAQ
Protagenic Therapeutics 的股票代號是什麼?▼
根據交易所不同,股票代號可能會有所差異。例如,在 Boerse Muenchen 交易所,Protagenic Therapeutics 的股票以代號 MBPC.MU 進行交易。
Protagenic Therapeutics 下一次財報日期是什麼時候?▼
Protagenic Therapeutics 將於 August 18, 2026 公布下一次財報。
Protagenic Therapeutics 去年的營收是多少?▼
Protagenic Therapeutics 去年的營收為 0EUR。
Protagenic Therapeutics 去年的淨利是多少?▼
MBPC.MU 去年的淨收益為 -5.17MEUR。
Protagenic Therapeutics 有多少名員工?▼
截至 July 10, 2026,公司共有 1 名員工。
Protagenic Therapeutics 位於哪個產業?▼
Protagenic Therapeutics從事於Health & Wellness產業。
Protagenic Therapeutics 何時完成拆股?▼
Protagenic Therapeutics 最近沒有進行任何拆股。
Protagenic Therapeutics 的總部在哪裡?▼
Protagenic Therapeutics 的總部位於 美國 的 Santa Barbara。